Proteomics-based discovery of biomarkers for paediatric acute lymphoblastic leukaemia: challenges and opportunities

There are important breakthroughs in the treatment of paediatric acute lymphoblastic leukaemia (ALL) since 1950, by which the prognosis of the child majority suffered from ALL has been improved. However, there are urgent needs to have disease‐specific biomarkers to monitor the therapeutic efficacy and predict the patient prognosis. The present study overviewed proteomics‐based research on paediatric ALL to discuss important advances to combat cancer cells and search novel and real protein biomarkers of resistance or sensitivity to drugs which target the signalling networks. We highlighted the importance and significance of a proper phospho‐quantitative design and strategy for paediatric ALL between relapse and remission, when human body fluids from cerebrospinal, peripheral blood, or bone‐marrow were applied. The present article also assessed the schedule for the analysis of body fluids from patients at different states, importance of proteomics‐based tools to discover ALL‐specific and sensitive biomarkers, to stimulate paediatric ALL research via proteomics to ‘build’ the reference map of the signalling networks from leukemic cells at relapse, and to monitor significant clinical therapies for ALL‐relapse.

• Publication year

  2014

• Venue

  Journal of Cellular and Molecular Medicine

• Publication date

  2014-06-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/jcmm.12319PMID 24912534PMCID 4124009
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Journal of Cellular and Molecular Medicine

  2014cited by this paper
• Prognostic implications of mutations in NOTCH1 and FBXW7 in childhood T‐all treated according to the NOPHO ALL‐1992 and ALL‐2000 protocols

  2014cited by this paper
• RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia

  2014cited by this paper
• Emerging techniques in molecular detection of circulating tumor cells

  2014cited by this paper
• Impact of mutations in FLT3, PTPN11 and RAS genes on the overall survival of pediatric B cell precursor acute lymphoblastic leukemia in Brazil

  2014cited by this paper
• The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches

  2013cited by this paper
• Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors

  2013cited by this paper
• Germline variants in MRE11/RAD50/NBN complex genes in childhood leukemia

  2013cited by this paper
• Multidrug resistance in relapsed acute myeloid leukemia: Evidence of biological heterogeneity

  2013cited by this paper
• A Natural-Like Synthetic Small Molecule Impairs Bcr-Abl Signaling Cascades and Induces Megakaryocyte Differentiation in Erythroleukemia Cells

  2013cited by this paper
• Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment

  2013cited by this paper
• New ionization processes and applications for use in mass spectrometry

  2013cited by this paper
• Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse

  2013cited by this paper
• Genetic loss of SH2B3 in acute lymphoblastic leukemia.

  2013cited by this paper
• Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL).

  2013cited by this paper
• Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia.

  2013cited by this paper
• Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner

  2013cited by this paper
• Developments in biobanking workflow standardization providing sample integrity and stability.

  2013cited by this paper
• Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia

  2013cited by this paper
• A case of pediatric B-Lymphoblastic leukemia presenting with a t(9;12)(p24;q11.2) involving JAK2 and concomitant MLL rearrangement with apparent insertion at 6q27

  2013cited by this paper
• [Deletions and rearrangements of PAX5 gene in B-lineage acute lymphoblastic leukemia].

  2013cited by this paper
• Regulatory Effects of Sestrin 3 (SESN3) in BCR-ABL Expressing Cells

  2013cited by this paper
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012cited by this paper
• Relevant phosphoproteomic and mass spectrometry: approaches useful in clinical research

  2012cited by this paper
• An insight into iTRAQ: where do we stand now?

  2012cited by this paper
• Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions

  2012cited by this paper
• Identification of prognostic protein biomarkers in childhood acute lymphoblastic leukemia (ALL).

  2011cited by this paper
• Mutational analysis in chronic myeloid leukemia: when and what to do?

  2011cited by this paper
• DIGE-based proteomic analysis identifies nucleophosmin/B23 and nucleolin C23 as over-expressed proteins in relapsed/refractory acute leukemia.

  2011cited by this paper
• Relapse of Acute Lymphoblastic Leukemia in Children in the Context of Microarray Analyses

  2011cited by this paper
• Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia

  2011cited by this paper
• Clinical proteomics of myeloid leukemia

  2010cited by this paper
• A rare chronic myeloid leukemia case with Philadelphia chromosome, BCR-ABL e13a3 transcript and complex translocation involving four different chromosomes.

  2010cited by this paper
• Identification of biphenyl-based hybrid molecules able to decrease the intracellular level of Bcl-2 protein in Bcl-2 overexpressing leukemia cells.

  2009cited by this paper
• Discovery and identification of potential biomarkers of pediatric Acute Lymphoblastic Leukemia

  2009cited by this paper
• Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

  2009cited by this paper
• A masked BCR/ABL rearrangement in a case of chronic myeloid leukemia with translocation t(3;9)(p14;q34).

  2008cited by this paper
• SIMAC (Sequential Elution from IMAC), a Phosphoproteomics Strategy for the Rapid Separation of Monophosphorylated from Multiply Phosphorylated Peptides*S

  2008cited by this paper
• Effects of blood sample handling procedures on measurable inflammatory markers in plasma, serum and dried blood spot samples.

  2008cited by this paper
• Chronic myeloid leukemia with a rare variant BCR-ABL translocation: t(9;22;21)(q34;q11.2;q11.2).

  2007cited by this paper
• Research progress in SELDI-TOF MS and its clinical applications

  2006cited by this paper
• Proteomic analysis of childhood leukemia

  2005cited by this paper
• Loss of heterozygosity in childhood acute lymphoblastic leukemia detected by genome-wide microarray single nucleotide polymorphism analysis.

  2005cited by this paper
• The development and application of imatinib

  2005cited by this paper
• Gene expression profiles and risk stratification in childhood acute lymphoblastic leukemia.

  2004cited by this paper
• Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis.

  1999cited by this paper
• Human B-cell progenitors and bone marrow microenvironment.

  1996cited by this paper
• Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. II. Potent cytotoxicity of 2-chloro-deoxyadenosine in acute lymphoblastic leukemia.

  1994cited by this paper
• Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. I. Cytotoxicity of interferon alpha in acute lymphoblastic leukemia.

  1993cited by this paper
• One patient's story.

  1993cited by this paper
• Stroma-supported immunocytometric assay (SIA): a novel method for testing the sensitivity of acute lymphoblastic leukemia cells to cytotoxic drugs.

  1993cited by this paper
• Cytotoxic drugs

  1985cited by this paper
• [Relationship between parameters of cell proliferation in acute human leukemia and the effect on those cells of antileukemic drugs in vivo].

  1972cited by this paper
• Potential antileukemic and immunosuppressive drugs. Preparation and in vitro pharmacological acitivity of some benzo-2,1,3-oxadiazoles (benzofurazans) and their N-oxides (benzofuroxans).

  1968cited by this paper

• Classification of small blue round cell tumors by integrating peptide and N-glycan mass imaging spectrometric profiles.

  2025cites this paper
• Integrated multi-omic analysis reveals novel subtype-specific regulatory interactions in pediatric B-cell acute lymphoblastic leukemia

  2025cites this paper
• Application of Omics Analyses in Pediatric B-Cell Acute Lymphoblastic Leukemia

  2025cites this paper
• Proteomic insights into paediatric cancer: Unravelling molecular signatures and therapeutic opportunities

  2024cites this paper
• A new insight updates in diagnosis and management of acute lymphoblastic leukemia, cytogenetics, immunophenotyping, and proteomic profile

  2023cites this paper
• How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper

  2022cites this paper
• Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine

  2022cites this paper
• Study of Glutathione S-transferase-P1 in cancer blood plasma after extraction by affinity magnetic nanoparticles and monitoring by MALDI-TOF, IM-Q-TOF and LC-ESI-Q-TOF MS.

  2021cites this paper
• Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma

  2020cites this paper
• Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia

  2020influential citation
• Single-Cell Diagnostics, Prognosis, and Therapy

  2019cites this paper
• Proteomic analysis of cerebrospinal fluid in pediatric acute lymphoblastic leukemia patients: a pilot study

  2019cites this paper
• Proteomic tools and new insights for the study of B-cell precursor acute lymphoblastic leukemia

  2019cites this paper
• Multi-omic approaches to improve outcome for T-cell acute lymphoblastic leukemia patients.

  2019cites this paper
• A systematic review of proteomic biomarkers associated with risk stratification in pediatric acute lymphoblastic leukemia

  2018cites this paper
• Omics techniques and biobanks to find new biomarkers for the early detection of acute lymphoblastic leukemia in middle-income countries: a perspective from Mexico.

  2017cites this paper
• Utilizing the Luminex Magnetic Bead-Based Suspension Array for Rapid Multiplexed Phosphoprotein Quantification.

  2017cites this paper
• Roles of immune microenvironment heterogeneity in therapy-associated biomarkers in lung cancer.

  2017cites this paper
• Differential expression pattern of protein markers for predicting chemosensitivity of dexamethasone-based chemotherapy of B cell acute lymphoblastic leukemia

  2017cites this paper
• Children as Biomarker Orphans: Progress in the Field of Pediatric Biomarkers.

  2017cites this paper
• Potentials of single‐cell biology in identification and validation of disease biomarkers

  2016cites this paper
• Elevated GAPDH expression is associated with the proliferation and invasion of lung and esophageal squamous cell carcinomas

  2015cites this paper
• Study of phosphorylation events for cancer diagnoses and treatment

  2015cites this paper
• A proteomic approach to obesity and type 2 diabetes

  2015cites this paper
• Application of oncoproteomics to aberrant signalling networks in changing the treatment paradigm in acute lymphoblastic leukaemia

  2014cites this paper